AI assistant
CORCEPT THERAPEUTICS INC — Director's Dealing 2021
Apr 28, 2021
30681_dirs_2021-04-27_077e327c-68c0-4a6d-8a29-71c591deea62.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2021-04-23
Reporting Person: Robb Gary Charles (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-23 | Common Stock | S | 10000 | $24.0219 | Disposed | 75638 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4564 | Indirect |
| Common Stock | 4564 | Indirect |
| Common Stock | 4564 | Indirect |
Footnotes
F1: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $24.00 to $24.065. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.